European Review for Medical and Pharmacological Sciences 2020; 24: 1548-1562

The role of gut microbiota in mediating obesity and diabetes mellitus

D. PITOCCO[1,2], M. DI LEO[1], L. TARTAGLIONE[1], F. DE LEVA[1], C. PETRUZZIELLO[1], A. SAVIANO[1], A. PONTECORVI[1], V. OJETTI[1,3]

[1]Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
[2]Department of Endocrinology, Università Cattolica del Sacro Cuore, Rome, Italy
[3]Department of Emergency Medicine, Università Cattolica del Sacro Cuore, Rome, Italy

Abstract. – OBJECTIVE: This review inspects the relations between the microbiota and the intestinal immune system in the advancement of metabolic illnesses, such as obesity and diabetes mellitus. The role of the microbiota in intestinal immune defense and the control of metabolism are subject to examination.

MATERIALS AND METHODS: In type 1 diabetes, the adhesion proteins prompt inside the intestinal epithelium prompt a more significant immune response that may result in the destruction of pancreatic β cells by CD8+ T-lymphocytes, as well as increased articulation of interleukin-17, which is associated with autoimmunity. Studies suggest that the beginning of metabolic ailments and certain co-morbidities can be viewed in light of the protection between the gut microbiota and the intestinal immune system. The gut microbiota is analyzed as a key regulator of metabolic ailments. Research demonstrates that obese patients with type 2 diabetes have a certain gut microbiota and that the microbiota is translocated from the gut to the tissues in conjunction with the illness, which instigates inflammation.

RESULTS: Research in animals and people suggests that a probiotic supplement may regulate the gut microbiota, thereby improving the prognosis for diabetes.

CONCLUSIONS: The mechanism underlying this phenomenon relates to a decrease in the inflammatory reaction and oxidative stress, as well as a decrease in leaky gut. Such reactions increase insulin sensitivity and reduce autoimmune responses.

Key Words:
Diabetes mellitus, Microbiota, Obesity, Inflammation, Oxidative stress.

Introduction

The intestinal tract is populated by massive amounts of microscopic organisms that are collectively known as the "gut microbiota". The microbiota is characterized as the intricate arrangement of intestinal microflora that live in harmony with the host, which has advantages for both parties. When the gut microbiota remains steady and separated from epithelial cells, it benefits the host, especially with regards to energy and immune development[1]. Estimates indicate that a single individual's microbiota is comprised of more than 100 trillion microorganisms, which are partitioned into 500-1,000 species. This number of microorganisms is ten times higher than the total number of cells that comprise the human body. The aggregate genome of the microbiota weighs 1.5 kg and has more than 3.3 million genes, which is 150 times the entire human genetic heritage. These genes are the basis for the survival of the different species, most of which live in the colon.

Most of the microbiota is composed of microscopic organisms, although it also includes viruses, fungi, and eukaryotic cells. Intestinal organisms are mostly anaerobic. More than 50 phyla are known, but two are predominant and cover 90% of the bacterial population in both humans and mice. The first are *Firmicutes* (gram-positive), which constitute 60-80% of the microbiota and include more than 200 genera (of which the most significant are *Ruminococcus, Clostridium*, and *Lactobacillus*). The second are *Bacteroidetes* (gram-negative, including *Bacteroides, Prevotella*, and *Xylanibacter*), which make up 20-30% of the microbiota, followed by *Actinobacteria* (gram-positive), which constitute around 10% of the microbiota (with a predominance of the genus *Bifidobacterium*). Proteobacteria, such as *Escherichia* and *Enterobacteriaceae*, are less common.

Researchers propose that the microbiota of most humans can be classified as one of three prevalent enterotypes, which are directed by

Corresponding Author: Dario Pitocco, MD; e-mail: dario.pitocco@policlinicogemelli.it

three distinct genera – *Bacteroides*, *Prevotella*, and *Ruminococcus*. The enterotypes are independent from age, sexual orientation, ethnicity, and weight history (BMI)[2]. The microorganisms are closely interlinked with each other and the host[3].

In recent years, the prevalence of metabolic illnesses in developed nations has increased exponentially. Certain simultaneous developments must be considered, including changes in the gut microbiota. One aim is to clarify the molecular source of metabolic infections, even though the huge contrasts and social differences among humans make this problematic. Over the past fifty years, advances in molecular science have enabled specialists to look at the hereditary qualities of metabolic ailments. The gut microbiota is related to an assortment of metabolic capacities, such as the maturation and ingestion of undigested carbohydrates, the retention of electrolytes and minerals, the balance of gut motility, and the synthesis of certain micronutrients[4]. Significant attention has been paid to the role of lactic acid in producing bacteria that lower pH, produce antimicrobial substances that affect pathogens, stimulate the immune system, integrate vitamins, and have anti-allergy effects (e.g., *Bifidobacterium* and *Lactobacillus*). In the past ten years, studies have pointed to a relationship between gut microbiota and the development of metabolic issues, especially diabetes mellitus (DM) and obesity. In addition, microbial adjustments in the human bowel have been presented as a potential reason for obesity[5]. Along with its metabolic capacities, the microbiota interfaces with the immune system, where it supports the development of resistant cells and ordinary microbiota. Studies[6,7] also have suggested that certain parts of the intestinal microbiota play key roles in various ailments, such as food allergies, malignant growths, incendiary intestinal ailments, cardiovascular diseases, and dyslipidaemia.

Main Text

The growing interest in microbiota has led to an exponential increase in the number of publications focused on this topic. Efforts are underway to examine the connection between the microbiota and the increase in such diseases as DM and obesity[8]. Some hypotheses suggest that changes in the intestinal microbiota lead to increased intestinal porousness and a mucosal immune response, thereby adding to the advancement of DM. The decrease in tight junction proteins prompts increased intestinal permeability, with microorganisms encouraging the translocation of bacterial lipopolysaccharide (LPS), possibly leading to metabolic endotoxemia and insulin obstruction[9,10]. In one of the main trials involving obese animals, the proportions of the gut phyla *Bacteroidetes* and *Firmicutes* were changed by reducing *Bacteroidetes* and increasing *Firmicutes*[11]. In a recent study[12], the microscopic organisms were evident in external areas of the bodily fluid layer in non-obese, non-diabetic subjects, while in obese people with DM, microorganisms could be found in the thick internal bodily fluid and in close proximity to the epithelium (Figure 1). The overall advantages of these phyla are associated with an increased ability to draw energy from food and low-grade inflammation. An increase in *Firmicutes* and a decrease in *Bacteroidetes* has been seen in obese mice. This is associated with the presence of explicit genes that encode proteins that make polysaccharides indigestible, as well as the creation of monosaccharides and short-chain fatty acids (SCFA) in the liver (Figure 2). This system may prompt increased supplement take-up and deposition by the gut microbiota with a comparable increase in metabolic disorders[13].

Both environmental and genetic components add to the pathogenesis of type 2 diabetes (T2D)[14,15]. T2D is the result of an increase in the generation of glucose in the liver and a decrease in the emission and activity of insulin. In T2D, a poor-quality part is communicated in tissues associated with digestion control, such as the liver, adipose tissue, and muscle tissue[16]. This metabolic inflammation is characterized by moderate cytokine generation, including interleukin-(IL-) 6, IL-1, or tumor necrosis factor alpha (TNFα), which adversely influence cell insulin flags and prompt insulin resistance and DM[17,18]. Low-grade inflammation starts with increased weight. Some researches[19,20] report that the gut microbiota is a significant independent factor in the improvement of DM. The human gut has trillions of microorganisms, including more than 1,000 microscopic organisms in 1,000 animal groups[21]. In this paper, we present information on changes in the gut microbiota in both type 1 diabetes (T1D) and T2D. We also summarize the mechanisms that may link the gut microbiota to DM. Various investigations have found changes in the gut microbiota in diabetic groups. However, there are no reliable findings concerning the species that are affected by these modifications in diabetic



Figure 1. Changes to the gut microbiota and intestinal barrier function in DM. Bacterial encroachment – a shrinking of the "bug-free" zone adjacent to the colonic epithelium – is a feature of human metabolic syndrome. Encroachment is associated with inflammatory bowel disease and with obesity in patients with diabetes. Under normal physiological conditions in the lean state, the gut microbiota is highly diversified. The intestinal barrier prevents pathogenic bacteria from penetrating the gut through the production of mucin. Intestinal epithelial cells produce tolerogenic responses to microbe-specific molecules of commensal bacteria bound to pattern-recognition receptors by secreting anti-inflammatory mediators. In obesity and/or diabetes mellitus, the gut flora is diversified and creates an imbalance in the ratio of bacterial species. It reduces the production of mucin and other anti-microbial factors, which allows for easier penetration of bacteria beyond the gut barrier. Pro-inflammatory cytokines produced by immune cells in response to the inflammatory milieu impair the epithelial barrier. A weakened gut barrier allows leakage of bacterial products, such as bacterial lipopolysaccharide, across the barrier and into the systemic circulation. High levels of bacterial lipopolysaccharide and bacterial products cause endotoxemia and systemic inflammation, which worsen metabolic disease.

patients. In addition, detailed investigations into the mechanisms that connect the gut microbiota to DM are lacking.

T1D is a proinflammatory issue that results in the pulverization of pancreatic islet beta cells and the loss of insulin generation[22]. Although the triggers of T1D have not yet been determined, studies suggest that, in addition to hereditary qualities, ecological factors and microbial contaminations might be significant[23]. Recent investigations propose that the intestinal microbiome plays a key role in the mechanism(s) behind this proinflammatory issue[24].

T2D is associated with intestinal mucosal harm[9,25], which might have several sources. First, small intestinal mucosal wounds may be caused by gut microbial dysbiosis in diabetic patients. In metagenome-wide research into gut microbial substance, the proportions of some butyrate-producing microorganisms were found to be reduced in patients with T2D, while the proportions of opportunistic pathogens were increased[26]. In addition, Sato et al[27] found a higher rate of gut microbes in the circulatory system in diabetic patients, which led them to propose that microscopic organisms translocate from the digestive tract to the circulatory system. Second, one of the consequences of DM, microangiopathy, might account for inflammatory variations in the small intestine. Third, diabetic neuropathy could cause intestinal wounds. Diabetic patients have a higher rate of abnormal intestinal motility, which is attributed to autonomic neuropathy[28]. Intestinal motility disorders are common after effects of gut



Figure 2. The action of gut microbiota is needed to digest some polysaccharides. The gut microbiota converts polysaccharides into monosaccharides and short-chain fatty acids (SCFA). These SCFAs are able to bind and activate two G-protein-coupled receptors (GPR41 and GPR43) of the gut epithelial cells. The activation of these receptors induces peptide YY. Starch digestion is an example of this process: H2 is produced and its increase inhibits starch digestion, at which point other bacterial groups work to transform the H2 into methane.

microbial dysbiosis and bacterial translocation, which may lead to mucosal damage[29]. Fourth, the capacity of intestinal stem cells may change profoundly in DM patients. Recent researches[30] suggest that the proportions of insulin-like development factor 1 (IGF-1) and insulin-like development factor-binding protein (IGFBP-3) change in DM patients.

The Role of the Microbiota in Diabetes

The gut microbiota is part of a dynamic ecosystem, and it is modified at the phylum and class levels by a variety of natural and host factors that affect the gut and other organs. Consequently, the gut microbiota is related to several human diseases, including obesity and DM[31,32]. Even though an understanding of the connection between the gut microbiota and T2D is essential, there are still several gaps in our knowledge that should be addressed. For instance, the entire microscopic bacteria population of the gut has not been characterized by subjects' age, sex, or medical treatment in order to limit sources of variation. The resistance of muscle and fat tissue to insulin activities evident in T2D is chiefly the consequence of a mix of hereditary factors, body composition, nutritional variables, and environmental elements. Insulin-receptor, glucose-transporter, and post-receptor changes are apparent in T2D. Moreover, peripheral tissues known to interminable compensatory hyperinsulinemia rise as resistant to insulin[33].

The intestinal microbiota plays a key role in metabolic diseases. In obese and diabetic subjects, researchers have found changes in the proportions of *Firmicutes*, *Bacteroidetes*, and *Proteobacteria*[8]. Pyrosequencing procedures have made significant advances in our understanding of the human microbiota. Diabetic patients have lower counts of *Bifidobacterium* and *Faecalibacterium prausnitzii*, which are Gram-positive[34] with anti-inflammatory properties[35]. In contrast to non-diabetic subjects, diabetic patients have lower levels of butyrate-creating bacteria, such as *Roseburia intestinalis* and *F. prausnitzii*, and elevated amounts of *Lactobacillus gasseri* (*L. gasseri*), *Streptococcus mutans* (*S. mutans*), and some strains of *Clostridium* (Table I). They also have higher levels of Proteobacteria, and expanded articulation of the microbiota qualities associated with oxidative pressure and inflammation[36,37]. In studies that compare metabolically healthy individuals to insulin-resistant, obese individuals, noteworthy changes are found in the latter[38].

A few studies have attempted to characterize the impact of the microbiota on insulin resistance. One study demonstrated that the reduced number

Table I. Dominant bacteria in human microbiota.

Firmicutes (60-80%)
Ruminiococcus
Clostridium
Lactobacillus
Bacteroidetes (20-30%)
Bacteroides
Prevotella
Xylanibacter
Actinobacteria (< 10%)
Bifidobacterium
Proteobacteria (< 1%)
Escherichia
Enterobacteriaceae

of *Bifidobacterium* and *Lactobacillus* and the diminished ratio of *Firmicutes* to *Bacteroidetes* were fundamentally associated with higher plasma glucose levels, while the higher quantities of *Clostridium* were associated with a higher HbA1c in T1D. These results[39,40] contradict the findings for T2D patients (Table II). These outcomes suggest some level of gut microbial dysbiosis in DM, even though there are differences in the affected species. Other distinctions may be identified in conjunction with certain topographical areas, ages, or sexual orientations, as well as different food habits.

The gut microbiota hydrolyzes and ferments the dietary polysaccharides to create monosaccharides and short-chain unsaturated fats (SCFAs) that the host can utilize for energy. SCFAs, such as acetate, propionate, and butyrate, generally supply 5% to 10% of human energy resources[41]. The signaling activities of SCFAs are affected by endogenous ligands of the G protein-coupled receptors 41 (GPR41) and 43 (GPR43), which are mainly represented in adipocytes and recognized as receptors of unsaturated fats[42,43]. DM, especially T2D, is related to a group of important lipid metabolism abnormalities[44]. At the point when contrasted and GF mice, the degree of triglycerides in mice was higher in the adipose tissues and the liver, while it was lower in serum. This suggests that the gut microbiota plays a role in lipid metabolism[45]. The mechanism through which unsaturated fats are discharged from triglyceride-rich lipoproteins to the muscle and heart is affected by the fasting-induced adipose factor[46]. The gut microbiota also builds an amalgamation of hepatic triglycerides and increases the production of hepatic triglycerides. The low-grade, chronic systemic inflammation contributes to the establishment of insulin resistance, DM, and obesity[29,30]. The increased circulating concentration of plasma lipopolysaccharide (LPS), which is described as metabolic endotoxemia, is a trigger in the safeguarding of a low-tone continuous inflammatory state in the host in light of high-fat weight-control diet plans[9,47].

Increase in Endotoxemia

T2D corresponds to a pro-inflammatory state with increased production of cytokines, such as IL-6, IL-1, or tumor necrosis factor, which negatively affects insulin's interaction with its receptors and adds to insulin resistance and DM. Increased weight appears to be one variable producing this low-grade inflammation. Experiments on animals have demonstrated that adjustments in the microbiota may change the grade of adipose tissue inflammation.

Increased flowing lipopolysaccharide (LPS) levels have been found in subjects with more prominent fat intake[48,49]. Lipopolysaccharide binding protein (LBP) is an acute-phase protein created in the liver that flows in the blood. LBP starts the recognition of LPS and strengthens the host's immune response to LPS[50], which focuses on the proportion of powerful lipopolysaccharides and could be a dependable biomarker that connects the lipopolysaccharide load to the subsequent immune response[51]. Circulating LBP is expanded in glucose-intolerant men[52], and it is an inflammatory marker associated with obesity-related insulin resistance[53]. Sun et al[54] found that an increase in circulating LBP is related to obesity, the Mets, and T2D. LPS are consumed by enterocytes and conveyed in plasma, where they are bound to chylomicrons[55]. In mice, achieving a balance in the intestinal microbiota using pre-

Table II. Bacterial species related to occurrence of insulin resistance and type 2 diabetes mellitus (T2DM).

	Increased in T2DM	Decreasedin T2DM
Bacterial phylum		
Firmicutes	X	
Bacteroidetes		X
Bacterial species		
Roseburia		X
Eubacterium halii		X
Faecalibacterium prauznitzii		X
Lactobacillus gasseri	X	
Streptococcus mutans	X	
Escherichia coli	X	
	X	

biotics acts positively on the intestinal barrier, as it lowers the high-fat-diet-initiated LPS endotoxemia, as well as systemic and liver inflammation[33,56]. LPS plays a causative role, as the addition of LPS to regular mice feed leads to insulin resistance in the liver, glucose tolerance, and an increase in adipose tissue. LPS ties to the CD14/TLR4 receptor in macrophages and prompts an increase in the creation of pro-inflammatory molecules. When LPS infusions were controlled in mice with hereditary nonappearance of the CD14/TLR4 receptor, the mice did not exhibit these metabolic qualities, and they did not develop T2D or obesity. This demonstrates the key role of the CD14/TLR4 receptor for LPS. Likewise, the knockout CD14/TLR4 mice were much more sensitive to insulin than wild-type controls[57]. This suggests a change in the extent of gram-negative bacteria in the bowel in certain circumstances. On the other hand, there might be a distinction in intestinal permeability, with the goal that LPS increments in serum, which is legitimately identified with the level of insulin resistance. A connection between LPS and T2D advancement been exhibited in some clinical trials[48,57-60]. In accordance with metabolic endotoxemia, live bacteria are translocated from the intestinal wall into the blood as T2D advances[61,62]. The multiplication of bacteria in the intestinal mucosa does not require an increase in glucose in the short term, but it may be related to the chronic, low-grade inflammation that leads to the insulin obstruction that characterizes T2D[12].

Changes in Incretin Emission Identified with Insulin Resistance and Beta Cell Work

Research has demonstrated that increases in *Bifidobacterium spp.* decrease inflammation in obese mice by increasing the generation of glucagon-like peptide-1 (GLP-1). This diminishes intestinal permeability. There is also evidence that the increase in *Bifidobacterium spp.* prompted by some prebiotics is connected to higher emissions of GLP-1 and peptide YY by the bowel. These two molecules have beneficial impacts, as they decrease insulin resistance and enhance beta cell function[63].

Variations in Gut Microbiota

The value of the microbiota and the ability to adjust it for medical purposes are no longer discussed. Results can be accomplished using prebiotics, probiotics, and antibiotics. The dietary routine changes the synthesis of the microbiota and the metagenome's expression independently from the host genome[64,65]. Studies focused on the Mediterranean diet have provided significant data on the effects of diet on the gut microbiota of obese subjects. These effects help counteract the progression of T2D[66]. When obese subjects consume a low-calorie diet that is low in fat and sugars, they experience an increase in *Bacteroidetes* and a decrease in *Firmicutes*[67,68]. The use of probiotics and prebiotics appears to alter gut microbiota and improve starch digestion[69]. Bacteria-fermenting carbohydrates, such as *Bifidobacterium* and *Lactobacillus*, have been given as a key component of prebiotic treatments in populations of various ages[67]. When mice on a high-fat regimen were fed prebiotics containing oligofructose, their *Bifidobacteria* levels were reestablished, their endotoxemia declined, and their glucose tolerance improved[70]. Other research indicates that red wine consumption might balance the development of intestinal flora in humans by increasing the quantities of *Enterococcus, Prevotella, Bacteroides, Bifidobacterium, Bacteroides uniformis, Eggerthella lenta, Blautia coccoides*, and *Eubacterium rectangle*, while diminishing LPS. This suggests that red wine polyphenols may have prebiotic benefits[71,72]. Another line of mediation is the utilization of probiotics containing live bacterial strains, including *Bifidobacterium* and *Lactobacillus* species, as dietary enhancements. These probiotics can positively affect intestinal flora. In mice, probiotics containing certain strains of *Lactobacillus* have been found to have an antidiabetic impact with a concomitant decrease in endotoxemia[56,73,74]. Treatment of hereditarily obese mice fed a fat-rich regimen with anti-microbials (ampicillin in addition to neomycin) led to changes in their microbiota and reductions in their insulin resistance and weight. In addition, animals given anti-toxin treatments exhibited a significant reduction in the degree of inflammation, oxidative pressure, and macrophage penetration in adipose tissue[75,76]. Another study[77] demonstrated an improvement in starch digestion following the destruction of *Helicobacter pylori*.

Gut microbiota transplantation was first utilized in patients who developed pseudomembranous colitis after *Clostridium difficile* contaminations that were treated with anti-infection agents. In these patients, fecal material transplanted from healthy donors seemed to reestablish microbial equalization in the gut by replacing the more

pathogenic intestinal bacterial strains with other, more useful strains[78]. This treatment has been used in connection with other gastrointestinal illnesses, which has opened up for new uses in such ailments as obesity, DM, and cardiovascular disease[79,80]. Some researches concentrate on males with insulin resistance and metabolic disorders who receive an autologous fecal microbiota transplant or an allogeneic transplant from thin donors[80]. Subjects who received transplants from thin donors experienced a significant improvement in peripheral sensitivity to insulin. They also experienced enhanced microbial diversity in the bowel and an increase in butyrate-producing microorganisms. Vrieze et al[81] found changes in gut microbiota with significant convergences of *Lactobacillus gasseri* and *Streptococcus mutans* (both living in the proximal bowel), as well as *Escherichia coli*, which could help predict the probability of insulin-resistance advancement in postmenopausal women. The outcomes of these small-scale studies have not been reproduced in other groups, but they have motivated the development of better systems for recognizing the gut microbiota and its potential properties.

Recent studies suggest the presence of synergies between the intestinal microbiota and the immune system in DM. The intestinal mucosa is a significant site for pathogen aggression. When uninjured, it acts as the primary line of defense against antigens. The intestinal wall is comprised of a layer of bodily mucus, IgA-secreting cells, antimicrobial peptides, and a complex epithelial barrier system shaped by the grip and tight intersections[82]. The immune response is regulated by the gut microbiota, and intestinal bacteria have been shown to affect the pathogenesis of T1D[83]. T1D is a notable immune-system illness that is characterized by lymphocytic infiltration or inflammation in pancreatic islets, which is typically identified with the invasion of innate immune cells. Increased intestinal permeability may increase the assimilation of antigens, which can damage pancreatic β cells[84]. Individuals susceptible to T1D and other autoimmune system diseases exhibit intestinal hindrances[85], which prompt an increase in antigens. The cytokines created by innate immune cells in the gut could disable β cells by advancing β cell apoptosis and islet-explicit T cell infiltration. This suggests a connection between intestinal microbiota and the immune system in T1D[86,87].

After treatment with a mix of antibiotics (metronidazole, neomycin, and polymyxin), nonobese diabetic (NOD) pregnant mice show significant variations in the peripheral composition of the T cell compartment, alterations in their offspring, and a higher recurrence of groups of separation (CD3+CD8+ T cells) in the mesenteric lymph nodes. Lymphocytic infiltration into the pancreatic islets is also somewhat lower in the descendants of NOD mice and there are changes in the groups of gut microbiota[88]. Other findings indicate that treatment with vancomycin shields NOD mice from T1D in the early postnatal period and builds the group of separation (CD 4+ T cells). The proportions of Gram-positive and Gram-negative microorganisms decline with the exception of *Akkermansia muciniphila*[89]. *Akkermansia muciniphila* is abundant in the gut microbiota of healthy people. It can act locally by fortifying the gut obstruction (traded off in non-obese diabetic mice), thereby enhancing the generation of bodily fluid and thickening the bodily fluid layer. This could maintain a strategic distance from its infiltration by inflammatory symbionts, which could lead to the observed decrease in plasma endotoxaemia[90]. The increased population of *Akkermansia muciniphila* initiates Foxp3 regulatory T cells in instinctive adipose tissues and essentially improves glucose tolerance. These outcomes indicate that balancing the immune system through the use of *Akkermansia muciniphila* may be a potential treatment for DM[91].

T2D has traditionally been seen as a metabolic illness. However, Depommier et al[92] suggest a relationship between the immune system and the pathogenesis of T2D. The obesity-related chronic inflammation and β cell stress caused by glucose toxicity and lipotoxicity could lead to both intrinsic and versatile resistance in T2D. The local or generalized immune system responses activate TLRs and nucleotide-restricting oligomerization area (NOD) receptors, and enhance the creation of cytokines, such as IL-1β, which crush β cells[92-94].

An in-depth understanding of the effect of the gut microbiota and the invulnerable framework on DM allows for further investigation. The natural invulnerable framework could be actuated by TLR, which initiates dendritic cell development and inflammatory cytokine discharge and supports the activation of T cells[95]. TLR5, a part of the innate immune system that is communicated in the intestinal mucosa, is significant in the improvement of metabolic syndromes[96]. TLR5-deficient mice display hyperphagia and develop metabolic diseases, including hyperlipid-

emia, hypertension, insulin resistance, and obesity. After transplantation of the gut microbiota from TLR5-deficient mice to their wide-type GF partners, an increase in proinflammatory cytokines and aspects of metabolic illnesses, including insulin resistance and obesity, have been found in the recipients[97]. The increased inflammatory mediators in DM produce oxidative and endoplasmic reticulum stress in pancreatic islet β cells, which determine insulin sensitivity and glucose homeostasis[98]. This demonstrates that the cooperation between the immune system and the intestinal microbiota helps to improve metabolic disorders. However, the underlying mechanisms remain poorly understood and reliable outcomes have not been described. For instance, two recent studies[99,100] found no association among insufficiency of TLR5 in mice, changes in the gut microbiota, and metabolic disorders, such as obesity and intestinal inflammation.

Novel Strategies Focusing on the Role of Gut Microbiota in Diabetes

Experimental and clinical investigations have demonstrated that focusing on the gut microbiota may be a powerful method for anticipating and overseeing DM[101,102]. The gut microbiota is mostly affected by diet. Prebiotics are food components that offer a health advantage by modifying the gut microbiota. They include inulin, fructo-oligosaccharides, galacto-oligosaccharides, and lactulose[103]. The restorative impacts of prebiotics on metabolic infections were affirmed in a preliminary clinical trial. Six obese volunteers with T2D and hypertension were fed a strict vegetarian diet for one month. Their metabolic parameters, including body weight, triglyceride levels, and HbA1c, fundamentally improved, as did their fasting glucose and postprandial glucose. The vegetarian diet prompted compositional changes in the gut microbiota, including a diminished ratio of *Firmicutes* to *Bacteroidetes* and an increase in Bacteroides fragilis and *Clostridium*, which reduced intestinal irritation and SCFA levels[104]. Another area of therapeutic interest is probiotics – live microorganisms ingested as either food or supplements. Probiotics are a class of live microorganisms that, when ingested, may offer health advantages[105], including immune-system stimulation, lower blood cholesterol, protection against respiratory and intestinal illnesses, and a decrease in fiery reactions. This is because probiotics have the ability to discharge antimicrobial substances, contend with different pathogens, and fortify the intestinal barrier[106]. *Bifidobacteria* and *Lactobacilli* are the most widely utilized strains in supplements[107]. Yadav et al[108] shows that the ingestion of 300 grams of a probiotic yogurt (Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12) per day for about a month and a half decreases blood 11 glucose and HbA1c levels in T2D patients. An antidiabetic impact of probiotics was also found in mice fed with a supplement of *Lactobacillus acidophilus* and *Lactobacillus cases*[108]. Qin et al[26] demonstrate that subjects with T2D experience moderate intestinal dysbiosis and an increase in the quantity of opportunistic gut pathogens (more than an adjustment in a particular microbial animal variety) that are directly connected with the pathophysiology of T2D. Moreover, they found a reduction in butyrate-creating microbes. An analysis of genetic, bacterial capacities suggests an increase in capacities identified with the reaction to intestinal oxidative stress, which are associated with an inclination toward diabetic complications[109]. Moreover, an ongoing report indicates that metformin, which is widely used in the treatment of T2D, prompts an increase in Escherichia and Bifidobacterium and a decrease in *Intestinibacter*[110].

Fecal transplants have been subjected to expanding consideration as a therapeutic procedure[111]. Vrieze et al[112] considered the impacts of moving the intestinal microbiota from thin subjects to male recipients with metabolic syndrome. A month and a half after the introduction of the gut microbiota, the insulin affectability of the recipients and their degrees of butyrate-creating intestinal microbiota had both increased fundamentally[111]. The outcomes of the exchange of gut microbiota for DM in mice have also been examined. After the exchange of microorganisms from MyD88-inadequate NOD mice, insulitis, and the beginning of DM improved. In addition, following oral transfers of fecal bacteria for more than three weeks, the gut microbiota was modified in terms of an increase in *Lachnospiraceae* and *Clostridiaceae* and a decrease in *Lactobacillaceae*[112]. These outcomes demonstrate that the oral organization of gut microbiota may be a conceivable method for improving insulin affectability in DM. In any case, the safety of fecal microbiota transplantation should be explored, as negative impacts have also been found. For instance, two patients passed on in an examination, including 18 patients who experienced bacterial transplantations to treat intermittent *Clostridium difficile* colitis[113]. Clinical studies and basic discourse

on fecal microbiota transplantation should help decide whether this method is useful for diabetic patients in general. In addition, more attention should be paid to the wellbeing, safety, and composition of donor microbiota.

Aas et al[114] found that the intestinal microbiome in obese patients could not effectively utilize tryptophan (TRP), a significant amino acid constituent of human proteins and the reason for the generation of cell transmitters. In obese patients, TRP was utilized to deliver kynurenine instead of being utilized to create indoles (anti-inflammatory compounds), which had negative consequences for glucose tolerance. Another situation for the connections among intestinal microbiome, inflammatory, and cardiometabolic hazard has been



Figure 3. Schematic reproduction of probiotic actions in Type 1 and Type 2 diabetes. Probiotic utilization increases the number of bifidobacteria and expanded expression of adhesion proteins reduces intestinal permeability, thereby damaging the activation of TLR4 by LPS. Consequently, NFkB activation pathways are impeded. The induction of TH17 cells is also repressed, which avoids pancreatic infiltration of CD8+ T cells.

speculated. Interleukin-22 and the estimation of kynurenine/tryptophan are two new elements that could immediately be brought into clinical practice as a therapeutic agent (IL-22) and as a biomarker of intestinal dysbiosis (KYN/TRP) in the testing of metabolic syndrome.

Conclusions

The establishment of a link between gut microbiota and metabolic ailments has recently motivated exponential advances in research. Multiple factors lead to changes in gut microbiota and affect the relationship between gut microbiota and T2D. Molecular mechanisms, including the anti-diabetic impacts of probiotics, have not been fully investigated, but they might include a decrease in oxidative stress, immunomodulation, attenuation of inflammation, and modification of the intestinal microbiota (Figure 3)[115]. In the future, larger human investigations that consider the majority of the conceivable confounding variables (e.g., age, gender, ethnicity, diet, and genetic factors) should enable us to effectively utilize the gut microbiota's composition and develop novel indicative or therapeutic strategies for the treatment of metabolic diseases.

Conflict of Interest

The Authors declare that they have no conflict of interests.

References

1) Hooper LV, Macpherson AJ. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nature Rev Immunol 2010; 10: 159-169.
2) Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Doré J; MetaHIT Consortium, Antolín M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo Minardi R, M'rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P. Enterotypes of the human gut microbiome. Nature 2011; 473: 174-180.
3) Rodriguez-Valera F, Martin-Cuadrado AB, Rodriguez-Brito B, Pasić L, Thingstad TF, Rohwer F. Explaining microbial population genomics though phage predation. Nature Rev Microbiol 2009; 7: 828-836.
4) Gill R, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-1359.
5) Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102: 11070-11075.
6) Holmes E, Li JV, Athanasiou T, Ashrafian H, Nicholson JK. Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. Trends Microbiol 2011; 19: 349-359.
7) Larsen N, Vogensen FK, Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5: e9085.
8) Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444, 1022-1023.
9) Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008; 57: 1470-1481.
10) Secondulfo M, Lafusco D, Carratu R, deMagistris L, Sapone A, Generoso M, Mezzogiomo A, Sasso FC, Cartenì M, De Rosa R, Prisco F, Esposito V. Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type I diabetic patients. Dig Liver Dis 2004; 36: 35-45.
11) Ley RE. Obesity and the human microbiome. Curr Opin Gastroent 2010; 26: 5-11.
12) Chassaing B, Raja SM, Lewis JD, Srinivasan S, Gewirtz AT. Colonic microbiota encroachment correlates with dysglycemia in humans. Cell Mol Gastroenterol Hepatol 2017; 4: 205-221.
13) Erejuwa OO, Sulaiman SA, Wahab MSW. Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges. Int J Mol Sci 2014; 15: 4158-4188.
14) Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science 2005; 307: 380-384.
15) Hofe CR, Feng L, Zephyr D, Stromberg AJ, Hennig B, Gaetke LM. Fruit and vegetable intake, as reflected by serum carotenoid concentrations, predicts reduced probability of polychlorinated biphenyl-associated risk for type 2 diabetes: National Health and Nutrition Examination Survey 2003-2004. Nutr Res 2014; 34: 285-293.
16) Pickup JC, Crook MA. Is type II diabetes mellitus a

disease of the innate immune system? Diabetologia 1998; 41: 1241-1248.

17) Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.

18) Shoelson S, Lee J, Goldfine A. Inflammation and insulin resistance. J Clin Invest 2006; 116, 1793-1801.

19) Burcelin R, Serino M, Chabo C, Blasco-Baque V, Amar J. Gut microbiota and diabetes: from pathogenesis to therapeutic perspective. Acta Diabetol 2011; 48, 257-273.

20) Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-1267.

21) Neish AS. Microbes in gastrointestinal health and disease. Gastroenterology 2009; 136: 65-80.

22) Rodriguez-Valera F, Martin-Cuadrado AB, Rodriguez-Brito B, Pasi´c L, Thingstad TF, Rohwer F, Mira A. Explaining microbial population genomics though phage predation. Nature Rev Microbiol 2009; 7: 828-836.

23) Gill SR, Pop M, Deboy RT, Eckburg, Turnbaugh PJ, Samuel BS, Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE. Metagenomic analysis of the human distal gut microbiome. Science 2006; 312: 1355-1359.

24) Cani PD, J. Amar J, M.A. Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, Waget A, Delmée E, Cousin B, Sulpice T, Chamontin B, Ferrières J, Tanti JF, Gibson GR, Casteilla L, Delzenne NM, Alessi MC, Burcelin R. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772.

25) Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 2005; 102: 11070-11075.

26) Qin J, Li Y, Cai Z, Li S, Zhu, Zhang JF, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012; 490: 55-60.

27) Sato J, Kanazawa A, Ikeda F, Yoshihara Y, Goto H, Abe H, Komiya K, Kawaguchi M, Shimizu T, Ogihara T, Tamura Y, Sakurai Y, Yamamoto R, Mita T, Fujitani Y, Fukuda H, Nomoto K, Takahashi T, Asahara T, Hirose T, Nagata S, Yamashiro Y, Watada H. Gut dysbiosis and detection of "live gut bacteria" in blood of Japanese patients with type 2 diabetes. Diabetes Care 2014; 37: 2343-2350.

28) Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.

29) Ding S, Chi MM, Scull BP, Rigby R, Schwerbrock NM, Magness S, Jobin C, Lund PK. High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 2010; v5: e12191.

30) Zhong HJ, Yuan Y, Xie WR, Chen MH, He XX. Type 2 diabetes mellitus is associated with more serious small intestinal mucosal injuries. PLoS One 2016; 11: e0162354.

31) Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65.

32) Human Microbiome Project C. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486: 207-214.

33) Abdul-Ghani MA, Defronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomedic Biotechnol 2010, 476279: 2010.

34) Furet JP, Kong LC, Tap J, Poitou C, Basdevant A, Bouillot JL, Mariat D, Corthier G, Doré J, Henegar C, Rizkalla S, Clément K. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010; 59: 3049-3057.

35) O'Mahony D, Murphy S, Boileau T, Park J, O'Brien F, Groeger D, Konieczna P, Ziegler M, Scully P, Shanahan F, Kiely B, O'Mahony L. Bifidobacterium animalis AHC7 protects against pathogen-induced NF-kappaB activation in vivo. BMC Immunol 2010; 11: 63.

36) Palau-Rodriguez M, Tulipan S, Queipo-Ortuño MI, Urpi-Sarda M, Tinahones FJ, Andres-Lacueva C. Metabolomic insight into the intricate gut microbial host interaction in the development of obesity and type 2 diabetes. Front Microbiol 2015; 6: 1151.

37) Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut 2014; 63: 1513-1521.

38) Serino M, Fernández-Real JM, García-Fuentes E, Queipo-Ortuño MI, Moreno-Navarrete JM, Sánchez A. The gut microbiota profile is associated with insulin action in humans. Acta Diabetol 2013; 50: 753-761.

39) Karlsson FH, Tremaroli V, Nookaew I, Bergström G, Behre CJ, Fagerberg B, Nielsen J, Bäckhed F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013; 498: 99-103.

40) Murri M, Leiva I, Gomez-Zumaquero JM, Tinahones FJ, Cardona F, Soriguer F, Queipo-Ortuño MI. Gut

microbiota in children with type 1 diabetes differs from that in healthy children: a case-control study. BMC Medicine 2013; 11: 46-50.

41) McNeil NI. The contribution of the large intestine to energy supplies in man. Am J Clin Nutr 1984; 39: 338-342.

42) Dentin R, J.P. Pegorier, F. Benhamed, F. Foufelle, P. Ferré, V. Fauveau, Magnuson MA, Girard J, Postic C. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem 2004; 279: 20314-20326.

43) Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, Daniels D, Muir AI, Wigglesworth MJ, Kinghorn I, Fraser NJ, Pike NB, Strum JC, Steplewski KM, Murdock PR, Holder JC, Marshall FH, Szekeres PG, Wilson S, Ignar DM, Foord SM, Wise A, Dowell SJ. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J Biol Chem 2003; 278: 11312-11319.

44) Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27: 1496-1504.

45) Velagapudi VR, Hezaveh R, Reigstad CS, Gopalacharyulu P, Yetukuri L, Islam S, Felin J, Perkins R, Borén J, Oresic M, Bäckhed F. The gut microbiota modulates host energy and lipid metabolism in mice. J Lip Res 2010; 51: 1101-1112.

46) Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. P Natl Acad Sci USA 2007; 104: 979-984.

47) Chervonsky A. Innate receptors and microbes in induction of autoimmunity. Curr Opin Immunol 2009; 21: 641-647.

48) Creely SJ, McTernan PG, Kusminski CM, Fisher FM, Da Silva NF, Khanolkar M. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Phys-End Met 2007; 292: E740-E747.

49) Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 1286-1292.

50) Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ. Structure and function of lipopolysaccharide binding protein. Science 1990; 249: 1429-1433.

51) Lepper P, Schumann C, Triantafilou K, Rasche F, Schuster T, Frank H, Schneider E, Triantafilou M, von Eynatten M. Association of lipopolysaccharide-binding protein and coronary artery disease in men. J Am Coll Cardiol 2007; 50: 25-31.

52) Gubern C, Lopez-Bermejo A, Biarnes J, Vendrell J, Ricart W, Fernandez-Real JM. Natural antibiotics and insulin sensitivity: the role of bactericidal/permeability-increasing protein. Diabetes 2006; 55: 216-224.

53) Moreno-Navarrete JM, Ortega F, Serino M, Luche E, Waget A, Pardo G, Salvador J, Ricart W, Frühbeck G, Burcelin R, Fernández-Real JM. Circulating lipopolysaccharide-binding protein (LBP) as a marker of obesity-related insulin resistance. J Obes 2012; 36: 1442-1449.

54) Sun L, Z. Yu, X. Ye, S. Zou, H. Li, D. Yu, Wu H, Chen Y, Dore J, Clément K, Hu FB, Lin X. A marker of endotoxemia is associated with obesity and related metabolic disorders in apparently healthy Chinese. Diabetes Care 2010: 33: 1925-1932.

55) Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 2009; 15, 1546-1558.

56) Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50: 2374-2383.

57) Pussinen PJ, Havulinn AS, Lehto M, Sundvall J, Salomma V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 2011; 34: 392-397.

58) Dixon AN, Valsamakis G, Hanif MW, Field A, Boutsiadis A, Harte A, McTernan PG, Barnett AH, Kumar S. Effect of the orlistat on serum endotoxin lipopolysaccharide and adipocytokines in South Asian individuals with impaired glucose tolerance. Int J Clin Pract 2008; 62, 1124-1129.

59) Al-Attas AO, Al-Daghri NM, Al-Rubeaan K, da Silva NF, Sabico SL, Kumar S, McTernan PG, Harte AL. Changes in endotoxin levels in T2DM subjects on anti-diabetic therapies. Cardiovasc Diabetol 2009; 8: 20.

60) Ghanim H, Abuaysheh S, Sia CL, Korzeniewski K, Chaudhuri A, Fernandez-Real JM, Dandona P. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes Care 2009; 32: 2281-2287.

61) Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermúdez-Humarán LG, Smirnova N, Bergé M, Sulpice T, Lahtinen S, Ouwehand A, Langella P, Rautonen N, Sansonetti PJ, Burcelin R. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011; 3: 559-572.

62) Amar J, Serino M, Lange C, Chabo C, Iacovoni J, Mondot S, Lepage P, Klopp C, Mariette J, Bouchez O, Perez L, Courtney M, Marre M, Klopp P, Lantieri O, Doré J, Charles M, Balkau B, Burcelin R; D.E.S.I.R. Study Group. Involvement of tissue bacteria in the onset of diabetes in humans: evidence for a concept. Diabetologia 2011; 54: 3055-3061.

63) Velasquez-Manoff M. Gut microbiome: the peacekeepers. Nature 2015; 518: S3-S11.

64) Falk PG, Hooper LV, Midtvedt T, Gordon JI. Creating and maintaining the gastrointestinal ecosys-

tem: what we know and need to know from gnotobiology. Microbiol Mol Biol Rev 1998; 62, 1157-1170.

65) Parashar A, Udayabanu M. Gut microbiota regulates key modulators of social behavior. Eur Neuropsychopharmacol 2016; 26: 78-91.

66) Haro C, Montes-Borrego M, Rangel-Zúniga OA, Alcalá-Díaz JF, Gómez-Delgado F, Pérez-Martínez P, Delgado-Lista J, Quintana-Navarro GM, Tinahones FJ, Landa BB, López-Miranda J, Camargo A, Pérez-Jiménez F. Two healthy diets modulate gut microbial community improving insulin sensitivity in human obese population. J Clin Endocrinol Metab 2016; 101: 233-242.

67) Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD. Linking long-term dietary patterns with gut microbial enterotypes. Science 2011; 334: 105-108.

68) Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, Almeida M, Quinquis B, Levenez F, Galleron N, Gougis S, Rizkalla S, Batto JM, Renault P; ANR MicroObes consortium, Doré J, Zucker JD, Clément K, Ehrlich SD. Dietary intervention impact on gut microbial gene richness. Nature 2013; 500: 585-588.

69) Rastall RA, Gibson GR, Gill HS, Guarner F, Klaenhammer TR, Pot B, Reid G, Rowland IR, Sanders ME. Modulation of the microbial ecology of the human colon by probiotics, prebiotics and symbiotics to enhance human health: an overview of enabling science and potential applications. FEMS Microbiol Ecol 2005; 52: 145-152.

70) Meyer D, Stasse-Wolthuis M. The bifidogenic effect of inulin and oligofructose and its consequences for gut health. Eur J Clin Nutr 2009; 63: 1277-1289.

71) Queipo-Ortuño MI, Boto-Ordóñez M, Murri M, Gomez-Zumaquero JM, Clemente-Postigo M, Estruch R, Cardona Diaz F, Andrés-Lacueva C, Tinahones FJ. Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. Am J Clin Nutr 2012; 95: 1323-1334.

72) Clemente-Postigo M, Queipo-Ortuño MI, Boto-Ordoñez M, Coin-Araguez L, Roca-Rodriguez MM, Delgado-Lista J, Cardona F, Andres-Lacueva C, Tinahones FJ. Effect of acute and chronic red wine consumption on lipopolysaccharide concentrations. Am J Clin Nutr 2013; 10, 1-9.

73) Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007; 23: 62-68.

74) Boto-Ordóñez M, Urpi-Sarda M, Queipo-Ortuño MI, Tulipani S, Tinahones FJ, Andres-Lacueva C. High levels of bifidobacteria are associated with increased levels of anthocyanin microbial metabolites: a randomized clinical trial. Food Funct 2014; 5: 1932-1938.

75) Hernández E, Bargiela R, Diez MS, Friedrichs A, Pérez-Cobas AE, Gosalbes MJ, Knecht H, Martínez-Martínez M, Seifert J, von Bergen M, Artacho A, Ruiz A, Campoy C, Latorre A, Ott SJ, Moya A, Suárez A, Martins dos Santos VA, Ferrer M. Functional consequences of microbial shifts in the human gastrointestinal tract linked to antibiotic treatment and obesity. Gut Microbes 2013; 4: 306-315.

76) Membrez M, Blancher F, Jaquet M, Bibiloni R, Cani PD, Burcelin RG, Corthesy I, Macé K, Chou CJ. Gut microbiota modulation with norfloxacin and ampicillin enhances glucose tolerance in mice. FASEB J 2008; 22: 2416-2426.

77) Roca-Rodríguez MM, Coín-Aragüez L, Cornejo-Pareja I, Alcaide J, Clu-Fernández C, Muñoz-Garach A, Durán-Martín E, Mora-Navas L, Gómez-Pérez AM, Molina-Vega M, Diaz-Perdigones C, Mancha-Doblas I, Tinahones FJ. Carbohydrate metabolism improvement after Helicobacter pylori eradication. Diab Metab 2016; 42, 130-134.

78) Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415.

79) Smits LP, Bouter KEC, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology 2013; 145: 946-953.

80) Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, Groen AK, Hoekstra JB, Stroes ES, Nieuwdorp M. The therapeutic potential of manipulating gut microbiotain obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 112-120.

81) Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012; 143: 913-916.

82) Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2010; 298: G807-G819.

83) Atkinson MA, Chervonsky A. Does the gut microbiota have a role in type 1 diabetes? Early evidence from humans and animal models of the disease. Diabetologia 2012; 55: 2868-2877.

84) Vehik K, Dabelea D. The changing epidemiology of type 1 diabetes: why is it going through the roof? Diabetes Metab Res Rev 2011; 27: 3-13.

85) Neu J, Reverte CM, Mackey AD, Liboni K, Tuhacek-Tenace LM, Hatch M, Li N, Caicedo RA, Schatz DA, Atkinson M. Changes in intestinal morphology and permeability in the biobreeding rat before the onset of type 1 diabetes. J Ped Gastroenterol Nutr 2005; 40: 589-595.

86) Szablewski L. Role of immune system in type 1 diabetes mellitus pathogenesis. Int Immunopharmacol 2014; 22: 182-191.

87) Vaarala O. Is the origin of type 1 diabetes in the gut? Immunol Cell Biol 2012; 90: 271-276.

88) Tormo-Badia N, Håkansson Å, Vasudevan K, Molin G, Ahrné S, Cilio CM. Antibiotic treatment of pregnant non-obese diabetic (NOD) mice leads to altered gut microbiota and intestinal immunological changes in the offspring. Scand J Immunol 2014; 80: 250-260.

89) Hansen CH, Krych L, Nielsen DS, Vogensen FK, Hansen LH, Sørensen SJ, Buschard K, Hansen AK. Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse. Diabetologia 2012; 55: 285-2294.

90) Hänninen A, Toivone R, Pöysti S, Belzer C, Plovier H, Ouwerkerk JP, Emani R, Cani PD, De Vos WM. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut 2018; 67: 1445-1453.

91) Mithieux G. Does Akkermansia muciniphila play a role in type 1 diabetes? Gut 2018; 67: 1373-1374.

92) Depommier C; Everard A; Druart C; Plovier H; Van Hul M; Vieira-Silva S; Falony G; Raes J; Maiter D; Delzenne NM; de Barsy M; Loumaye A; Hermans MP; Thissen JP; de Vos WM; Cani PD. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med 2019; 25: 1096-1103.

93) Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-305.

94) Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.

95) Medzhitov R. Origin and physiological roles of inflammation. Nature 2011; 454: 428-435.

96) Letran SE, Lee SJ, Atif SM, Uematsu S, Akira S, McSorley SJ. TLR5 functions as an endocytic receptor to enhance flagellinspecific adaptive immunity. Eur J Immunol 2011; 41: 29-38.

97) Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, Sitaraman SV, Knight R, Ley RE, Gewirtz AT. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010; 328: 228-231.

98) Hasnain SZ, Borg DJ, Harcourt BE, Tong H, Sheng YH, Ng CP, Das I, Wang R, Chen AC, Loudovaris T, Kay TW, Thomas HE, Whitehead JP, Forbes JM, Prins JB, McGuckin MA. Glycemic control in diabetes is restored by therapeutic manipulation of cytokines that regulate beta cell stress. Nat Med 2014; 20: 1417-1426.

99) Chassaing B, Ley RE, Gewirtz AT. Intestinal epithelial cell toll-like receptor 5 regulates the intestinal microbiota to prevent low-grade inflammation and metabolic syndrome in mice. Gastroenterology 2014; 147: 1363-1377.

100) Ubeda C, Lipuma L, Gobourne A, Viale A, Leiner I, Equinda M, Khanin R, Pamer EG. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR deficient mice. J Exp Med 2012; 209: 1445-1456.

101) Stenman LK, Waget A, Garret C, Klopp P, Burcelin R, Lahtinen S. Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. Benef Microbes 2014; 5: 437-445.

102) Ogawa A, Kadooka Y, Kato K, Shirouchi B, Sato M. Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum nonesterified fatty acid levels in Japanese hypertriacylglycerolemic subjects. Lipids Health Dis 2014; 13: 36-44.

103) Pineiro M, Asp NG, Reid G, Macfarlane S, Morelli L, Brunser O, Tuohy K. FAO Technical Meeting on Prebiotics. J Clin Gastroenterol 2008; 42: S156-S159.

104) Kim MS, Hwang SS, Park EJ, Bae JW. Strict vegetarian diet improves the risk factors associated with metabolic diseases by modulating gut microbiota and reducing intestinal inflammation. Environ Microbiol Rep 2013, 5: 765-775.

105) WHO-World Health Organization: Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria, Joint WHO/FAO Expert Consultation on Geneva. Cordoba, Argentina: WHO; 2001.

106) Gill H, Prasad J. Probiotics, immunomodulation, and health benefits. Adv Exp Med Biol 2008; 606: 423-454.

107) Prasad J, Gill HS, Smart JB, Gopal PK. Selection and characterization of Lactobacillus and Bifidobacterium strains for use as probiotics. Int Dairy J 1998; 8: 993-1002.

108) Yadav H, Jain S, Sinha PR. Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition 2007; 23: 62-68.

109) Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V. Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition 2012; 28, 539-543.

110) Kashyap P, Farrugia G. Oxidative stress: key player in gastrointestinal complications of diabetes. Neurogastroenterol Motil 2011; 23: 111-114.

111) Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Mannerås-Holm L, Ståhlman M, Olsson LM, Serino M, Planas-Fèlix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R, Fernàndez-Real JM, Bäckhed F. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med 2017; 23: 850-858.

112) Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with meta-

bolic syndrome. Gastroenterology 2012; 143: 913-916.

113) Peng J, Narasimhan S, Marchesi JR, Benson A, Wong FS, Wen L. Long term effect of gut microbiota transfer on diabetes development. J Autoimmun 2014; 53: 85-94.

114) Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36: 580-585.

115) Laurans L, Venteclef N, Haddad Y, Chajadine M, Alzaid F, Metghalchi S, Sovran B, Denis RGP, Dairou J, Cardellini M, Moreno-Navarrete JM, Straub M, Jegou S, McQuitty C, Viel T, Esposito B, Tavitian B, Callebert J, Luquet SH, Federici M, Fernandez-Real JM, Burcelin R, Launay JM, Tedgui A, Mallat Z, Sokol H, Taleb S. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota mediated metabolic health. Nat Med 2018; 24: 1113-1120.